International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 04 Issue 10 October 2024

Page No: 1883-1889

DOI: https://doi.org/10.47191/ijmscrs/v4-i10-29, Impact Factor: 7.949

Clinical Management and Pathophysiology of Infective Endocarditis: An Updated Review of Diagnostic Challenges and Therapeutic Approaches

Donaldo Emiliano Silva López*[1], Pedro Luis Matus Rojo[2], Rubén Darío González Tellechea[3], Brenda Paola Flores González[4], Elissa Bracamontes Perez[5], Manuel Rodrigo Toledo Burgueño[4]

[1]Tecnológico de Monterrey Campus Monterrey, Nuevo Léon, Mexico.

[2]Universidad Autónoma de Sinaloa. Mexico

[3]Universidad autónoma de Durango campus Los Mochis. Sinaloa, Mexico.

[4]Universidad Autónoma de Guadalajara. Zapopan, Jalisco, México.

[5]Hospital General Hospital General de Los Mochis, Jesús Kumate Rodríguez. Secretaria de salud. Sinaloa, México.

ABSTRACT

Infective endocarditis (IE) is a severe and life-threatening condition characterized by infection of the endocardial surface of the heart, primarily affecting the heart valves. Despite advances in diagnostic techniques and antimicrobial therapies, IE remains associated with significant morbidity and mortality due to its complex pathogenesis and clinical variability. This article reviews the most recent developments in the pathophysiology, diagnostic criteria, and management strategies of infective endocarditis. Key issues such as microbial etiology, including common pathogens like *Staphylococcus aureus* and *Streptococcus* species, are discussed alongside less frequent organisms and their association with specific patient populations. The article emphasizes the importance of early diagnosis using advanced imaging modalities, such as echocardiography and PET-CT, and laboratory findings, particularly blood cultures. We explore both medical and surgical management strategies, highlighting the role of antibiotic therapy and the indications for valve surgery. A focus is given to the management of complex cases, including prosthetic valve endocarditis and infections in immunocompromised patients. The article aims to provide clinicians with a comprehensive understanding of the evolving landscape of infective endocarditis and its implications for patient outcomes.

KEYWORDS: endocarditis, infective, heart, staphylococcus aureus

ARTICLE DETAILS

Published On:
21 October 2024

Available on:
https://ijmscr.org/

EPIDEMIOLOGY

Infective endocarditis (IE) is a relatively rare but serious condition, with an estimated annual incidence ranging between 3 to 10 cases per 100,000 individuals globally. The epidemiology of IE has evolved significantly over the past decades, influenced by demographic shifts, changes in healthcare practices, and an increase in at-risk populations. Traditionally, IE was most commonly seen in individuals with predisposing cardiac conditions, such as rheumatic heart disease. However, in high-income countries, rheumatic heart disease has declined significantly, while degenerative heart diseases, the use of intracardiac devices, and prosthetic valves have emerged as key risk factors. In low- and middle-income countries, rheumatic heart disease remains a significant cause, contributing to the burden of IE.1,2

Aging populations in developed nations have further shifted the epidemiological landscape, as older adults are increasingly susceptible to IE due to factors like degenerative valve diseases, increased frequency of invasive medical procedures, and healthcare-associated infections. Prosthetic valve endocarditis (PVE), which occurs in about 20% of IE cases, is particularly prevalent in these populations, often with complex, multidrug-resistant organisms involved. 1,2

Intravenous drug use (IVDU)-associated endocarditis has also risen dramatically, particularly in certain regions where the opioid epidemic is prevalent. In these cases, *Staphylococcus aureus* is the predominant pathogen, with high virulence and a propensity for rapid valvular destruction, particularly in right-sided IE involving the tricuspid valve.1,2

Healthcare-associated IE has become more common due to the increased use of invasive procedures, such as catheterization and dialysis, as well as the presence of intracardiac devices, including pacemakers and defibrillators. Nosocomial infections, often due to resistant pathogens like methicillin-resistant *Staphylococcus aureus* (MRSA) and enterococci, pose significant challenges in this patient cohort.2,3

Geographically, the prevalence of specific pathogens varies. In developed countries, *Staphylococcus aureus* has surpassed *Streptococcus viridans* as the leading causative organism, responsible for 30-50% of cases. In contrast, *Streptococcus viridans* continues to be a major pathogen in regions where dental hygiene and access to healthcare may be limited. Less common pathogens, including *HACEK* organisms (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella), fungi, and *Coxiella burnetii* (the causative agent of Q fever endocarditis), tend to occur in immunocompromised patients or those with atypical exposures, such as zoonotic contact or prolonged antibiotic therapy.3,4

Mortality rates for IE remain high, ranging from 15% to 30%, depending on the causative pathogen, patient comorbidities, and the timeliness of intervention. Prosthetic valve endocarditis and cases caused by multidrug-resistant organisms carry particularly poor prognoses, necessitating aggressive and timely medical and surgical intervention.3,4

CLINICAL MANIFESTATIONS

The clinical presentation of infective endocarditis can vary widely, ranging from acute, rapidly progressive illness to a more indolent, subacute course, depending on the infecting organism, host factors, and the underlying cardiac condition. The clinical manifestations are often non-specific, complicating early diagnosis. A high index of suspicion is required, particularly in patients with known risk factors, such as prior valve disease, prosthetic valves, intravenous drug use, or recent invasive procedures.4,5

The classic triad of infective endocarditis consists of fever, a new or changing heart murmur, and evidence of embolic phenomena, though all three components are seen in only a minority of patients. Fever, present in up to 90% of cases, is typically the most common symptom. It is often low-grade in subacute cases but may be high and associated with rigors in acute, aggressive forms, particularly with pathogens like *Staphylococcus aureus*.4,5

Cardiac manifestations are central to the disease, with valvular involvement being the hallmark. The formation of vegetations—masses of platelets, fibrin, microorganisms, and inflammatory cells—on the heart valves leads to valvular insufficiency, heart failure, and, in severe cases, structural damage to the valve apparatus. A new or worsening murmur, due to valvular regurgitation, is a frequent finding, particularly in left-sided endocarditis affecting the mitral or aortic valves. Right-sided endocarditis, more common in intravenous drug users, frequently involves the tricuspid valve and is less likely to present with heart failure but more likely to cause septic pulmonary emboli.4,5

Embolic phenomena are a common and dangerous complication, occurring in 20-50% of cases. Emboli can travel to various organs, causing systemic or pulmonary embolism depending on the side of the heart affected. Left-sided IE can lead to embolic events such as stroke (due to cerebral emboli), splenic infarctions, renal infarctions, or peripheral arterial emboli. Right-sided IE is more often associated with septic pulmonary embolism, leading to respiratory symptoms, including pleuritic chest pain, cough, hemoptysis, or dyspnea.4,5

Vascular phenomena, including petechiae, Janeway lesions (non-tender hemorrhagic macules on palms and soles), and splinter hemorrhages, are also frequently seen. These are caused by immune complex deposition or septic emboli. Osler nodes (painful, erythematous nodules typically located on the fingers and toes) and Roth spots (retinal hemorrhages with pale centers) are less common but are considered classic findings of subacute IE.4,5,6

Neurological complications occur in up to 30% of cases and include stroke, cerebral abscess, meningitis, and encephalopathy, often resulting from embolic events or septic emboli to the brain. These neurological manifestations may be the presenting feature, especially in embolic strokes, which may occur before the diagnosis of IE is made.5,6

Renal manifestations include immune-mediated glomerulonephritis, which may present with hematuria, proteinuria, and renal dysfunction. Embolic renal infarction can also occur, leading to flank pain and hematuria.5,6

Immunological phenomena, including circulating immune complexes, are responsible for some of the systemic features of IE. For example, splenomegaly, arthritis, and vasculitis may be present in subacute cases. Laboratory findings often reflect systemic inflammation, with elevated inflammatory markers, such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), as well as anemia, leukocytosis, and microscopic hematuria.5,6

In summary, the clinical manifestations of infective endocarditis are highly variable and often depend on the chronicity of the infection, the infecting organism, and the host's underlying cardiac and immune status. Early recognition of these diverse clinical signs, combined with prompt diagnostic evaluation, is crucial to improving outcomes for this potentially fatal disease. 5,6

Novel and Current Diagnostic Methods in Infective Endocarditis

Infective endocarditis (IE) remains a diagnostic challenge due to its varied clinical presentation and the nonspecific nature of many of its early symptoms. Historically, the diagnosis of IE has relied on a combination of clinical suspicion, blood cultures, and echocardiographic evidence of valvular vegetations or complications. However, recent advancements in diagnostic modalities, particularly in imaging, microbiological techniques, and molecular diagnostics, have improved the ability to detect IE early and accurately, even in complex cases. This section reviews the most current and novel diagnostic methods that are shaping the modern approach to diagnosing infective endocarditis.6,7

1. Echocardiography: Refinements in Transthoracic and Transesophageal Echocardiography

Echocardiography continues to be the cornerstone of IE diagnosis, with both transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) playing critical roles. TTE is a non-invasive initial diagnostic tool, while TEE is preferred for its higher sensitivity, especially in detecting smaller vegetations, abscesses, and prosthetic valve involvement.6,7

Advancements in 3D echocardiography have significantly enhanced the visualization of valvular anatomy. This modality provides a more detailed and spatially accurate view of vegetations, valve perforations, and leaflet destruction, facilitating better pre-surgical planning. Three-dimensional TEE offers superior diagnostic accuracy for detecting small vegetations, abscesses, or fistulas that might not be visible on 2D imaging. It also enables real-time evaluation of valve function, which is particularly important in prosthetic valve endocarditis (PVE), where echocardiographic artifacts can obscure traditional 2D views.6,7

Additionally, **strain imaging and speckle-tracking echocardiography** are newer techniques that allow for the assessment of subtle myocardial dysfunction that may accompany IE, particularly in the presence of periannular abscesses or myocarditis secondary to septic emboli.6,7

2. Positron Emission Tomography-Computed Tomography (PET-CT)

Positron emission tomography-computed tomography (PET-CT) has emerged as a valuable tool in the diagnosis of both native valve endocarditis (NVE) and prosthetic valve endocarditis (PVE), particularly in complex cases where echocardiographic findings may be inconclusive. PET-CT works by detecting areas of increased metabolic activity, typically by using 18-fluorodeoxyglucose (FDG), which accumulates in areas of active infection or inflammation.6,7

In PVE, where the diagnosis is notoriously difficult due to the often small or obscured vegetations and artifacts caused by the prosthetic material, PET-CT can be crucial in identifying perivalvular complications, such as abscesses, that may not be apparent on echocardiography. The integration of metabolic imaging with anatomical localization provided by CT improves diagnostic accuracy in challenging cases. PET-CT also has utility in detecting septic emboli, allowing for the identification of metastatic infections (such as in the spleen, kidneys, or vertebrae) that may not be clinically apparent but alter treatment plans.6,7

Recent studies suggest that the **European Society of Cardiology (ESC)** guidelines have integrated PET-CT as a supplementary imaging modality for suspected PVE and cases where IE is suspected but not confirmed by traditional diagnostic criteria. The high sensitivity of PET-CT in identifying infection-related metabolic activity makes it particularly useful in subacute cases or those with low-grade infection.7,8

3. Cardiac Magnetic Resonance Imaging (MRI)

While cardiac magnetic resonance imaging (MRI) is not routinely used for the initial diagnosis of IE, it is increasingly being recognized for its ability to assess intracardiac and extracardiac complications, particularly in cases where echocardiography may be suboptimal. Cardiac MRI offers superior soft tissue contrast resolution, making it particularly valuable in detecting **perivalvular abscesses**, valve leaflet perforation, and myocardial involvement, which may be secondary to septic emboli or extension of the infection.7,8

Furthermore, cardiac MRI can provide detailed information on ventricular function and detect secondary complications of IE, such as myocardial ischemia or infarction caused by embolic events. In some cases, MRI can be employed to evaluate complications of right-sided IE, such as pulmonary emboli or infarcts, with greater accuracy than other imaging techniques.8,9

4. Blood Culture and Molecular Microbiological Advances

Traditional blood cultures remain the gold standard for identifying the causative organisms in IE, with positive cultures obtained in approximately 85% of cases. However, certain pathogens, including fastidious organisms or those associated with culture-negative endocarditis, pose significant diagnostic challenges. In these cases, novel molecular techniques are invaluable.8,9

Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS) are two cutting-edge molecular diagnostic techniques that have revolutionized the detection of culture-negative endocarditis. PCR can identify bacterial DNA in blood or tissue samples, even when cultures fail to grow an organism. For example, PCR is particularly useful for detecting fastidious organisms, such as *Coxiella burnetii*, *Bartonella* species, or *Tropheryma whipplei*, which are known to cause culture-negative endocarditis. NGS, with its ability to sequence entire microbial genomes, offers even greater sensitivity and specificity, allowing for the detection of rare or previously unidentified organisms in cases of difficult-to-diagnose IE.8,9

Moreover, **matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry** has accelerated the time to organism identification in positive blood cultures, allowing for more rapid initiation of targeted antimicrobial therapy. This technique provides highly accurate identification of bacterial and fungal species, including antibiotic-resistant strains, which is particularly important for optimizing the treatment of multidrug-resistant organisms such as methicillin-resistant *Staphylococcus* *aureus* (MRSA) or vancomycin-resistant enterococci (VRE).8,9

5. Serological Testing

Serological testing is another critical tool, especially for diagnosing culture-negative endocarditis caused by specific pathogens like *Coxiella burnetii* (Q fever endocarditis), *Bartonella* species, or *Brucella*. These tests are often combined with molecular techniques to enhance diagnostic accuracy. For example, **phase I IgG antibodies** against *Coxiella burnetii* at titers greater than 1:800 are highly indicative of chronic Q fever endocarditis.9

6. Intravascular Ultrasound (IVUS)

Intravascular ultrasound (IVUS) is a novel imaging modality used primarily in interventional cardiology but has found applications in diagnosing complex cases of IE. IVUS allows for detailed imaging of the coronary arteries and can provide valuable information in cases of IE involving perivalvular extension or those where coronary involvement is suspected. It offers high-resolution imaging of the vessel walls, helping to assess for the presence of vegetations, abscesses, or aneurysms that might not be apparent on traditional echocardiography or angiography.9

7. Hybrid Imaging Techniques

In recent years, the integration of multiple imaging modalities—referred to as **hybrid imaging**—has gained popularity in diagnosing IE, particularly in complex or ambiguous cases. The combination of PET-CT and echocardiography is a prime example, where metabolic imaging is used alongside structural imaging to provide a comprehensive assessment of infection location, activity, and complications.10

Another approach involves combining **CT angiography (CTA)** with echocardiography or MRI to evaluate both the heart and extracardiac structures, including the aorta and coronary arteries, to detect embolic complications or extension of the infection. Hybrid imaging techniques are particularly useful in PVE and device-related endocarditis, where traditional methods might be limited due to artifacts or inadequate visualization of prosthetic materials.10

The diagnostic approach to infective endocarditis has advanced significantly with the development of novel imaging modalities, molecular microbiological techniques, and integrated approaches that combine traditional diagnostics with cutting-edge technology. While echocardiography remains central to the diagnosis, the use of PET-CT, MRI, and molecular diagnostics has allowed for earlier, more accurate detection of both native and prosthetic valve endocarditis, as well as culture-negative cases. These advances are critical for guiding timely treatment, which is essential in improving clinical outcomes in this life-threatening condition.10

New Therapeutic Approaches in the Treatment of Infective Endocarditis

Infective endocarditis (IE) is a serious and potentially life-threatening condition that requires prompt and aggressive treatment to prevent complications such as heart failure, systemic embolization, and sepsis. Traditional management of IE has primarily involved prolonged antibiotic therapy, often lasting 4 to 6 weeks, and in many cases, surgical intervention to remove infected valvular tissue or repair damaged heart structures. While these approaches remain the backbone of therapy, recent advances in antimicrobial regimens, surgical techniques, and novel interventional methods are transforming the management of this complex disease. The emergence of new technologies and therapeutic strategies offers hope for better outcomes, particularly in challenging cases such as prosthetic valve endocarditis (PVE), multidrug-resistant infections, and patients with multiple comorbidities.11

1. Advances in Antimicrobial Therapy

The cornerstone of infective endocarditis treatment remains prolonged antibiotic therapy, aimed at eradicating the causative microorganism from the infected heart valve or endocardial surface. However, the rise of antibiotic-resistant organisms, such as methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant enterococci (VRE), and multidrug-resistant gram-negative bacteria, has prompted the exploration of novel antimicrobial agents and combination therapies to enhance bacterial clearance.12

a. Combination Antibiotic Therapy:

While monotherapy with beta-lactams or vancomycin has been standard for many cases of IE, combination antibiotic therapy is becoming increasingly common in certain clinical scenarios. For example, for *Enterococcus* species, which are notoriously difficult to treat due to their intrinsic resistance to many antibiotics, combination therapy with a beta-lactam and an aminoglycoside (such as gentamicin) is often recommended. However, concerns over nephrotoxicity with prolonged aminoglycoside use have led to alternative combination strategies, such as beta-lactams combined with **daptomycin** or **linezolid** in cases of multidrug resistance. Recent studies suggest that dual beta-lactam therapy (e.g., ampicillin plus ceftriaxone) may be equally effective with less toxicity compared to beta-lactam-aminoglycoside combinations.12

b. Newer Antibiotics:

Several newer antibiotics have shown promise in the treatment of resistant pathogens in IE. **Ceftaroline**, a fifth-generation cephalosporin, has demonstrated efficacy against MRSA and has been used successfully in cases of MRSA endocarditis, either as monotherapy or in combination with daptomycin. Additionally, **dalbavancin** and **oritavancin**, both lipoglycopeptides with extended half-lives, offer the advantage of once-weekly dosing, potentially allowing for outpatient therapy in stable patients. These agents are particularly useful in cases where vancomycin has failed or when toxicity limits its use.12

For gram-negative infections, especially those caused by multidrug-resistant organisms such as *Pseudomonas aeruginosa*or *Enterobacteriaceae*, **ceftolozane/tazobactam** and **meropenem/vaborbactam** are new beta-lactam/beta-lactamase inhibitor combinations that provide broader coverage against resistant strains. In certain cases of **culture-negative endocarditis**, especially when fungal infection is suspected, newer antifungal agents such as **isavuconazole** or **echinocandins** (e.g., caspofungin) may be indicated.12

2. Role of Surgery and Advances in Surgical Techniques

Surgery plays a critical role in the management of infective endocarditis, particularly in patients with heart failure due to severe valvular dysfunction, large vegetations with high embolic risk, abscess formation, or failure of antibiotic therapy. While conventional valve replacement surgery remains the gold standard, new surgical techniques and prosthetic materials have improved outcomes for patients undergoing surgery for IE.13

a. Timing of Surgery:
The timing of surgical intervention in IE has been a topic of debate, but recent studies suggest that **early surgery**, within the first week of diagnosis, may be beneficial in patients with large vegetations (>10 mm), severe valve regurgitation, or heart failure. Early surgery can reduce the risk of embolic events and may lead to better overall survival, particularly in patients with left-sided endocarditis. However, in cases of intracerebral emboli or hemorrhagic stroke, the timing of surgery must be carefully balanced to avoid perioperative complications.13

b. Prosthetic Valve Endocarditis (PVE):
Prosthetic valve endocarditis (PVE) poses unique challenges due to the presence of foreign material in the heart, which can harbor biofilm-forming microorganisms. Surgical removal of the infected prosthesis followed by valve replacement is often necessary in PVE, particularly when associated with abscesses or fistulae. Advances in **prosthetic valve design**, including the use of biologic scaffolds and newer synthetic materials with reduced thrombogenicity and infection risk, have improved long-term outcomes. The development of **valve-sparing surgeries** and the use of homografts (valves from human donors) or xenografts (from animal tissues) in select patients has also provided additional options for managing PVE.14

3. Minimally Invasive and Transcatheter Interventions

In patients who are at high surgical risk, minimally invasive and transcatheter approaches are emerging as valuable alternatives to conventional surgery. These techniques are particularly useful in elderly patients or those with multiple comorbidities, who may not tolerate open-heart surgery well.15

a. Transcatheter Aortic Valve Replacement (TAVR):
For patients with severe aortic valve endocarditis who are deemed unsuitable for surgery due to advanced age or other comorbid conditions, **transcatheter aortic valve replacement (TAVR)** has become an important therapeutic option. While traditionally used for aortic stenosis, TAVR is now being considered in cases of aortic regurgitation due to endocarditis, particularly in those with degenerative valve disease or prior aortic valve replacement. Although the long-term outcomes of TAVR in IE patients remain under investigation, early results are promising in select high-risk patients.15

b. Transcatheter Mitral Valve Repair (TMVR):
Similar to TAVR, **transcatheter mitral valve repair (TMVR)** using devices such as the **MitraClip** is being explored for patients with severe mitral valve regurgitation secondary to IE who are not candidates for open surgery. TMVR may offer a less invasive solution for repairing the damaged valve and restoring function without the need for full valve replacement.16

c. Percutaneous Vegetation Removal:
Another novel approach is **percutaneous removal of valvular vegetations** using devices such as the **AngioVac system**. This technique involves the aspiration of large, mobile vegetations that pose a high embolic risk, particularly in patients with right-sided IE affecting the tricuspid valve. The procedure is performed via a catheter-based system, reducing the need for open surgery and providing immediate removal of potentially dangerous vegetations. While still in the early stages of adoption, this approach shows potential for reducing embolic complications and improving outcomes in patients with large vegetations.16

4. Adjunctive Therapies

In addition to antibiotics and surgical interventions, novel adjunctive therapies are being explored to improve outcomes in IE.16

a. Antithrombotic Therapy:
The role of anticoagulation in infective endocarditis has been a subject of controversy due to the risk of embolic events and intracranial hemorrhage. However, in specific circumstances, particularly in patients with mechanical prosthetic valves, anticoagulation therapy remains necessary. Recent studies have explored the use of **direct oral anticoagulants (DOACs)** in place of traditional warfarin in select patients with mechanical valves or atrial fibrillation, although their safety in the setting of active infection is still under investigation.17

b. Immunomodulatory Therapies:
Given the significant immune response seen in infective endocarditis, immunomodulatory therapies are being considered as potential adjuncts to traditional treatments. **Intravenous immunoglobulin (IVIG)** and other immune-targeted therapies may help reduce the inflammatory burden in cases of severe IE, particularly in patients with underlying autoimmune conditions or those experiencing immune complex-mediated complications, such as

glomerulonephritis. Additionally, therapies aimed at modulating the cytokine response, such as **interleukin-6 inhibitors** or **TNF-alpha blockers**, are being investigated in the context of sepsis and severe systemic inflammation caused by IE.17

5. Personalized Medicine and Biomarker-Guided Therapy

The advent of personalized medicine and biomarker-guided therapy is reshaping the way clinicians approach infective endocarditis. Genetic testing and molecular profiling of both the host and the pathogen can provide critical insights into the optimal treatment strategy. For example, **pharmacogenomics** may guide the selection of antibiotics in patients with specific genetic polymorphisms that affect drug metabolism, thereby optimizing dosing and minimizing toxicity. Additionally, **biomarkers** such as **procalcitonin** and **C-reactive protein (CRP)** are being used to monitor the response to therapy and guide the duration of antibiotic treatment.17

The management of infective endocarditis has undergone significant transformation with the introduction of new antibiotics, advanced surgical techniques, minimally invasive interventions, and adjunctive therapies. These innovations offer the potential to improve survival, reduce complications, and enhance the quality of life for patients with this complex and potentially fatal disease. However, challenges remain, particularly in the treatment of multidrug-resistant infections and patients with prosthetic valve endocarditis. Ongoing research and clinical trials will continue to refine these.18

CONCLUSIONS

Infective endocarditis (IE) remains a challenging and life-threatening condition, characterized by significant morbidity and mortality despite advances in diagnostic modalities, therapeutic interventions, and surgical techniques. This multifaceted disease requires a multidisciplinary approach, incorporating expertise from cardiologists, infectious disease specialists, cardiothoracic surgeons, and other healthcare professionals. The complexity of IE is reflected in its varied etiology, clinical presentations, and potential complications, which range from heart failure and embolic phenomena to intracardiac abscess formation and systemic sepsis.

The evolution of diagnostic methods has significantly enhanced our ability to detect and characterize infective endocarditis early in its course. Advanced imaging techniques such as transesophageal echocardiography (TEE), ^18F-FDG PET/CT, and the integration of molecular diagnostic tools like PCR-based assays have provided clinicians with more accurate and timely identification of the causative pathogens, even in culture-negative cases. The incorporation of novel biomarkers, such as procalcitonin and CRP, in clinical practice aids in risk stratification, monitoring therapeutic response, and optimizing treatment duration, reducing unnecessary prolonged antibiotic use.

Therapeutic strategies for IE have also progressed, with a focus on individualized treatment plans based on pathogen susceptibility, patient comorbidities, and the presence of complications such as prosthetic valve involvement or multidrug-resistant organisms. The development of novel antibiotics like ceftaroline, daptomycin, and long-acting lipoglycopeptides (dalbavancin and oritavancin) has expanded the armamentarium against resistant pathogens, offering new hope in the treatment of MRSA, VRE, and multidrug-resistant gram-negative infections. These agents, along with combination regimens that reduce toxicity while preserving efficacy, are changing the landscape of antimicrobial therapy in IE.

Surgical intervention remains a cornerstone in the management of infective endocarditis, particularly in cases of heart failure, large vegetations with high embolic risk, and prosthetic valve endocarditis (PVE). Advances in early surgical timing, valve-sparing procedures, and the use of biologic and synthetic grafts have significantly improved outcomes in patients undergoing valve replacement or repair. Furthermore, minimally invasive techniques such as transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR) are emerging as viable alternatives for high-risk patients who are not surgical candidates.

The future of IE management lies in the integration of precision medicine, leveraging genetic and molecular insights to tailor antimicrobial therapy and guide surgical decision-making. Personalized approaches to antibiotic selection based on pharmacogenomics and biomarker-guided therapy offer the potential to improve therapeutic outcomes while minimizing adverse effects. Additionally, the exploration of immunomodulatory therapies and adjunctive treatments aimed at modulating the host’s immune response may provide novel avenues to mitigate the systemic complications of infective endocarditis.

In conclusion, while significant progress has been made in the diagnosis and treatment of infective endocarditis, many challenges persist. The rise of multidrug-resistant organisms, the complexity of managing prosthetic valve infections, and the delicate balance between timely surgical intervention and medical therapy require ongoing research and innovation. Multidisciplinary collaboration and adherence to evidence-based guidelines are paramount in improving patient outcomes. Future advances in molecular diagnostics, targeted antimicrobial therapy, and minimally invasive interventions will continue to shape the landscape of infective endocarditis treatment, offering the possibility of better survival rates and quality of life for affected patients.

REFERENCES

I. Geller, SA Infective endocarditis: a history of the development of its understanding *Autops Case Rep.* 2013; 3:5-12

II. Lerner, PI · Weinstein, L Infective endocarditis in the antibiotic era *N Engl J Med.* 1966; 274:199-206
III. Lerner, PI · Weinstein, L Infective endocarditis in the antibiotic era *N Engl J Med.* 1966; 274:259-266
IV. Lerner, PI · Weinstein, L Infective endocarditis in the antibiotic era *N Engl J Med.* 1966; 274:388-393
V. Hackett, AJ · Stuart, J Infective endocarditis: identification and management in the emergency department *Emerg Med Pract.* 2020; 22:1-24
VI. Wang, A · Athan, E · Pappas, PA · et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis *JAMA.* 2007; 297:1354-1361
VII. Chen, H · Zhan, Y · Zhang, K · et al. The global, regional, and national burden and trends of infective endocarditis from 1990 to 2019: results from the Global Burden of Disease Study 2019 *Front Med.* 2022; 9, 774224
VIII. Tleyjeh, IM · Steckelberg, JM · Murad, HS · et al. Temporal trends in infective endocarditis: a population-based study in Olmsted County, Minnesota *JAMA.* 2005; 293:3022-3028
IX. Slipczuk, L · Codolosa, JN · Davila, CD · et al. Infective endocarditis epidemiology over five decades: a systematic review *PLoS One.* 2013; 8, e82665
X. Polishchuk, I · Stavi, V · Awesat, J · et al. Sex differences in infective endocarditis *Am J Med Sci.* 2021; 361:83-89
XI. Hammond-Haley, M · Hartley, A · Al-Khayatt, BM · et al. Trends in the incidence and mortality of infective endocarditis in high-income countries between 1990 and 2019 *Int J Cardiol.* 2023; 371:441-451
XII. Shah, ASV · McAllister, DA · Gallacher, P · et al. Incidence, microbiology, and outcomes in patients hospitalized with infective endocarditis *Circulation.* 2020; 141:2067-2077
XIII. Li, HL · Tromp, J · Teramoto, K · et al. Temporal trends and patterns of infective endocarditis in a Chinese population: a territory-wide study in Hong Kong (2002–2019) *Lancet Reg Health West Pac.* 2022; 22, 100417
XIV. Yucel, E · Bearnot, B · Paras, ML · et al. Diagnosis and management of infective endocarditis in people who inject drugs: JACC state-of-the-art review *J Am Coll Cardiol.* 2022; 79:2037-2057
XV. Sengupta, SP · Prendergast, B · Laroche, C · et al. Socioeconomic variations determine the clinical presentation, aetiology, and outcome of infective endocarditis: a prospective cohort study from the ESC-EORP EURO-ENDO (European Infective Endocarditis) registry *Eur Heart J Qual Care Clin Outcomes.* 2022; 9:85-96
XVI. Noubiap, JJ · Nkeck, JR · Kwondom, BS · et al. Epidemiology of infective endocarditis in Africa: a systematic review and meta-analysis *Lancet Glob Health.* 2022; 10:e77-e86
XVII. Njuguna, B · Gardner, A · Karwa, R · et al. Infective endocarditis in low- and middle-income countries *Cardiol Clin.* 2017; 35:153-163
XVIII. Murdoch, DR · Corey, GR · Hoen, B · et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study *Arch Intern Med.* 2009; 169:463-473